Does TRT Help With Weight Loss? Testosterone Therapy and Fat Loss Evidence

Testosterone replacement therapy (TRT) is FDA-approved for classical hypogonadism — confirmed low morning total testosterone on at least two occasions plus consistent symptoms — not for weight loss in men with normal testosterone. In hypogonadal men, TRT reliably shifts body composition: fat mass goes down and lean mass goes up, often without a dramatic change in scale weight in the short term. Long-term observational registries (Saad 2013^[3], Saad 2016^[4]) report substantial sustained weight loss (~16–19% body weight at 5–8 years) in obese hypogonadal men on testosterone undecanoate. The randomized evidence (Ng Tang Fui 2016 BMC Med^[5], Wittert 2021 T4DM Lancet Diabetes Endocrinol^[7]) is more modest: TRT plus calorie deficit preserves lean mass and improves glycemia versus placebo plus calorie deficit, but the scale-weight delta in 2-year RCTs is small. TRAVERSE (Lincoff 2023 NEJM^[2]) settled cardiovascular safety in 5,246 men with cardiovascular risk. Compared with the FDA-approved obesity GLP-1 receptor agonists — semaglutide −14.9% in STEP-1^[9], tirzepatide −20.9% in SURMOUNT-1^[10] — TRT is an order of magnitude smaller as a pure weight-loss intervention. The honest summary: TRT is hormone replacement, not weight-loss therapy. If you have confirmed hypogonadism, it is a defensible part of a combined protocol. If you have normal testosterone, TRT will not produce meaningful weight loss and exposes you to monitoring burden and real risks.

The honest summary

• TRT is not an FDA-approved weight-loss therapy. It is hormone replacement for confirmed hypogonadism (Bhasin 2018 Endocrine Society Clinical Practice Guideline^[1]).
• Diagnosis requires two morning total testosterone measurements below ~264–300 ng/dL (lab reference range dependent) plus consistent symptoms (decreased libido, erectile dysfunction, fatigue, depressed mood, loss of body hair, decreased muscle mass, gynecomastia) per Bhasin 2018^[1].
• In obese hypogonadal men, long-term testosterone-undecanoate registries show substantial sustained weight loss: Saad 2013 reported −16 kg at 5 years in 255 men^[3]; Saad 2016 reported about −19% body weight at 8 years across 411 men with obesity classes I–III^[4].
• Randomized evidence is more conservative. Ng Tang Fui 2016 BMC Med^[5] randomized 100 obese hypogonadal men to testosterone or placebo plus a 600-kcal-deficit diet for 56 weeks. Both groups lost about 11 kg of body weight, but the testosterone arm preserved lean mass and lost more fat — about 6 kg additional fat reduction vs placebo.
• The body-composition gains are not durable after TRT is stopped. Ng Tang Fui 2017^[6] followed the same men for a year after discontinuation; fat mass returned and lean-mass gains reversed.
• The T4DM trial (Wittert 2021 Lancet Diabetes Endocrinol^[7]) randomized 1,007 men aged 50–74 with low testosterone and either impaired glucose tolerance or newly diagnosed T2DM. Testosterone undecanoate plus lifestyle reduced T2DM incidence at 2 years by 41% versus lifestyle alone (12% vs 21%).
• TRAVERSE (Lincoff 2023 NEJM^[2]) randomized 5,246 hypogonadal men with established cardiovascular disease or high cardiovascular risk to testosterone gel vs placebo. Testosterone was non-inferior for major adverse cardiovascular events (MACE; HR 0.96) but produced a signal for pulmonary embolism, atrial fibrillation, and acute kidney injury.
• Compared with GLP-1 obesity pharmacotherapy — semaglutide −14.9% body weight at 68 weeks in STEP-1^[9], tirzepatide −20.9% at 72 weeks in SURMOUNT-1^[10] — TRT is a far smaller weight intervention, particularly in men without baseline hypogonadism.
• TRT is not appropriate in men with prostate cancer, breast cancer, hematocrit above ~50%, severe untreated obstructive sleep apnea, uncontrolled heart failure, MI or stroke within the prior 3–6 months, desire for fertility in the near term, or significant symptomatic lower urinary tract symptoms (Bhasin 2018^[1]).

The hypogonadal-obesity cycle

Obesity and low testosterone reinforce each other in a bidirectional cycle that is now well documented in endocrinology textbooks and the Endocrine Society guideline^[1]. The mechanism in three steps:

1. Adipose tissue expresses aromatase, the enzyme that converts testosterone to estradiol. More body fat means more peripheral aromatization and a lower circulating testosterone level even when testicular output is preserved.
2. Higher estradiol and adipokine signals (leptin, inflammatory cytokines like IL-6 and TNF-alpha) suppress hypothalamic GnRH pulse frequency, which reduces pituitary LH secretion, which reduces Leydig-cell testosterone production. This is the “functional hypogonadism of obesity” phenotype: low T, normal-to-low LH, normal pituitary anatomy.
3. Lower testosterone in turn promotes visceral adiposity, reduces lean mass, lowers resting energy expenditure, and worsens insulin sensitivity. The net effect is a self-reinforcing loop where weight gain drives further testosterone suppression which drives further weight gain.

Two practical implications. First, the right first step for an obese man with low T is often weight loss, not TRT — modest sustained weight loss (5–10% of body weight) frequently restores testosterone into the normal range without exogenous hormone. Second, when weight loss is not feasible or has failed, TRT plus a structured weight-loss program is a defensible combination because it interrupts the cycle at two points simultaneously.

Diagnosing hypogonadism: the threshold and the workup

The Endocrine Society 2018 guideline^[1] is the current standard of care for testosterone-deficiency diagnosis in adult men. The core requirements:

• Two morning fasting total testosterone measurements drawn before 10 AM on separate days. Testosterone follows a diurnal rhythm with peak values in the early morning; afternoon or evening samples will under-report and produce false-positive hypogonadism diagnoses.
• A threshold below the lower limit of the normal range for healthy young men in the specific assay used — the Endocrine Society and CDC harmonized reference is roughly 264–300 ng/dL for total testosterone measured by mass spectrometry. Many commercial labs use immunoassay-based reference ranges that run slightly higher. The threshold is assay-specific; read the lab's own reference.
• Consistent symptoms. A low number alone is not enough; the diagnosis requires both biochemical confirmation and symptoms — low libido, erectile dysfunction, decreased frequency of morning erections, fatigue, depressed mood, decreased muscle bulk or strength, decreased body hair, gynecomastia, or hot flushes.
• Workup of the cause. Once hypogonadism is biochemically and clinically confirmed, the next step is to distinguish primary (testicular) from secondary (pituitary or hypothalamic) by measuring LH and FSH. Add SHBG and calculated free testosterone when total T is borderline or SHBG is suspected to be abnormal (obesity, insulin resistance, hyperthyroidism, liver disease). Add prolactin, ferritin (hemochromatosis screen), and morning cortisol when secondary hypogonadism is suspected, plus an MRI of the pituitary if LH is low and total T is severely low or there are red flags.

The diagnostic discipline matters. A single low afternoon T in a man with vague fatigue does not justify TRT. The cash-pay TRT-clinic ecosystem in the US has expanded rapidly and frequently dispenses testosterone without two-morning confirmation, without symptom verification, and without a differential diagnosis — that is not standard of care.

Body composition: TRT shifts fat to muscle

The most consistent finding across the TRT-in-hypogonadism literature is a shift in body composition, not necessarily a dramatic change in scale weight. Fat mass (particularly visceral fat) decreases; lean mass and bone mineral density increase. Two of the best-controlled studies:

Ng Tang Fui 2016 BMC Med^[5] randomized 100 obese men (BMI ≥30) with low total testosterone (≤12 nmol/L, roughly ≤346 ng/dL) and waist circumference ≥102 cm to testosterone undecanoate intramuscularly or placebo, with both groups enrolled in a very low energy diet program targeting a 600 kcal/day deficit. The trial ran 56 weeks. Findings:

• Both groups lost about 11 kg of total body weight — the testosterone arm did not lose dramatically more weight on the scale.
• The testosterone arm lost about 6 kg more fat mass than placebo.
• The placebo arm lost about 3 kg of lean mass. The testosterone arm preserved or modestly gained lean mass.
• The net effect: the testosterone arm ended the trial with a substantially more favorable body-fat percentage and lean-to-fat ratio at matched scale weight.

Ng Tang Fui 2017^[6] followed the same men for a year after testosterone discontinuation. The body-composition advantage of the testosterone arm reversed — fat mass returned and the lean-mass gain was lost. This is the durability lesson: TRT is a chronic therapy. Stopping it reverses the body-composition benefit on a timescale of months.

The Testosterone Trials (Snyder 2016 NEJM^[8]) ran seven coordinated 12-month RCTs in 790 men aged 65 and older with low T. The body-composition substudy confirmed lean-mass gain and fat-mass loss; the sexual-function substudy showed improvements in libido and erectile function; the vitality substudy showed only modest improvements; the cognition substudy was effectively null.

The long-term Saad registries: substantial weight loss sustained over years

The largest body of long-term TRT-and-weight-loss data comes from two German urology-clinic registries reported by Farid Saad and colleagues. These are observational — not randomized — so they cannot establish causation cleanly. But they are the only multi-year data available, and the magnitude is striking.

Saad 2013 Obesity (Silver Spring)^[3] reported on 255 hypogonadal men treated with testosterone undecanoate intramuscularly (1,000 mg every 12 weeks after a 6-week loading dose) and followed for up to 5 years. Mean weight loss was about −16 kg at 5 years, with waist circumference decreasing in parallel. Importantly, weight loss was progressive — the curve did not plateau early as it does with most lifestyle interventions.

Saad 2016 Int J Obes (Lond)^[4] extended the registry to 411 obese hypogonadal men across WHO obesity classes I, II, and III, with up to 8 years of follow-up. The headline number: about −19% body weight at 8 years, with the largest absolute losses in class III obesity (BMI ≥40). This is in the magnitude range of GLP-1 receptor agonist outcomes, achieved without a GLP-1.

Two important interpretive caveats. First, these registries are observational; men who stayed in the program for 5–8 years are a selected, adherent population, and there was no randomization. Second, the men also received structured clinical follow-up, which is itself a behavioral intervention. The RCTs (Ng Tang Fui 2016, T4DM) consistently show smaller scale-weight effects than the registries. Both signals are real; the truth is somewhere between them.

T4DM: TRT cut new T2DM by 41% in men with prediabetes

The most rigorous large RCT of TRT in the obesity-and-glucose-intolerance population is the T4DM trial (Wittert 2021 Lancet Diabetes Endocrinol^[7]). Design: 1,007 men aged 50–74 with a waist circumference ≥95 cm, screening total testosterone ≤14 nmol/L (~404 ng/dL), and either impaired glucose tolerance or newly diagnosed T2DM — randomized to testosterone undecanoate or placebo, both arms enrolled in a structured WW (Weight Watchers) lifestyle program, for 2 years. Primary endpoint: T2DM at 2 years (defined by 2-h OGTT glucose ≥11.1 mmol/L).

• T2DM at 2 years: 12% on testosterone vs 21% on placebo — a relative risk reduction of about 41%.
• Body weight: about −3.4 kg additional weight loss on testosterone vs placebo on top of the lifestyle program.
• Waist circumference, fat mass, grip strength, and erectile function all improved versus placebo.
• Hematocrit increased in the testosterone arm, and 22% of testosterone-treated men had hematocrit >54% at some point during the trial — the dominant safety signal.

T4DM is the strongest evidence to date that TRT, on top of a weight-loss program, reduces incident T2DM in men with prediabetes and low-to-low-normal testosterone. The evidence is specifically not a license for testosterone in eugonadal men or in men without glucose intolerance.

TRAVERSE: the cardiovascular safety question, finally settled

From the 2010 FDA black-box-warning era forward, the central unanswered question about TRT was cardiovascular safety. Early observational studies (Vigen 2013, Finkle 2014) suggested increased cardiovascular events; the FDA mandated a post-marketing trial. The result is TRAVERSE (Lincoff 2023 NEJM^[2]).

Design: 5,246 hypogonadal men aged 45–80 (mean ~63) with two morning T values <300 ng/dL plus symptoms of hypogonadism, plus either established cardiovascular disease or high cardiovascular risk, randomized to 1.62% testosterone gel daily (titrated to maintain T 350–750 ng/dL) vs placebo gel. Mean follow-up about 33 months. Primary endpoint: major adverse cardiovascular events (death from CV causes, non-fatal MI, or non-fatal stroke).

• MACE: 7.0% testosterone vs 7.3% placebo; HR 0.96 (95% CI 0.78–1.17), meeting the pre-specified non-inferiority margin.
• Pulmonary embolism: 0.9% vs 0.5% — a real signal consistent with prior label warnings.
• Atrial fibrillation: 3.5% vs 2.4%.
• Acute kidney injury: 2.3% vs 1.5%.
• Prostate cancer incidence: 0.5% vs 0.4% — no meaningful difference. This is reassuring but the trial was not powered for long-term prostate-cancer endpoints.
• Fracture risk was numerically higher on testosterone in the safety substudy (a counterintuitive finding given the known bone-density benefit).

Interpretation: in middle-aged-to-older hypogonadal men with cardiovascular risk, testosterone gel does not increase MACE compared with placebo. It does increase PE, AFib, and AKI in the relative-risk range that should be discussed before starting therapy, particularly in men with prior VTE, AFib history, or chronic kidney disease.

How TRT compares with weight-loss pharmacotherapy

Two takeaways. First, in head-to-head RCTs at matched durations, the GLP-1 receptor agonists are the larger weight-loss intervention — by roughly a 4–5x margin compared with TRT alone. Second, the long-term Saad registries reach magnitudes comparable to the GLP-1s, but the comparison is not clean because the registries are observational, longer in duration, and the men received structured clinical follow-up.

TRT plus GLP-1 stacking: an emerging clinical practice

Combining TRT with a GLP-1 receptor agonist (semaglutide, liraglutide, tirzepatide) is a question many men ask and many cash-pay clinics now offer. Three things matter:

1. There are no head-to-head RCTs of TRT plus GLP-1 vs GLP-1 alone for weight outcomes. This is an off-label combination in the weight-loss context. The data we have are case series, small open-label cohorts, and extrapolation from each agent's monotherapy trials.
2. The mechanisms are independent and plausibly additive. GLP-1s reduce caloric intake via appetite suppression and slowed gastric emptying. TRT shifts substrate partitioning toward muscle and away from fat through androgen-receptor signaling. Combining them in a hypogonadal man on a calorie deficit is biologically sensible: the GLP-1 produces the deficit, the TRT preserves lean mass and improves the fat-to-lean ratio.
3. The monitoring burden is the sum of both regimens. A man on TRT plus a GLP-1 needs the TRT labs (T, hematocrit, PSA, lipids every 3–6 months) plus GLP-1-related considerations (lipase if pancreatitis risk, eye exam if pre-existing retinopathy, nutritional adequacy at suppressed appetite, lean-mass preservation via protein and resistance training). Lean-mass preservation is actually the strongest theoretical argument for the combination — GLP-1 weight loss has a documented lean-mass-loss component (typically ~25–40% of total weight lost), and TRT counters it.

For most men, the order of operations should be: (1) confirm hypogonadism with two morning T plus symptoms, (2) start with the better-evidenced single intervention for the dominant problem (GLP-1 for the obesity, TRT for the hypogonadism symptoms), (3) reassess at 3–6 months before adding the second.

TRT modalities: how it is delivered

Testosterone is available in multiple formulations. Each has a different pharmacokinetic profile, monitoring requirement, and cost. The Endocrine Society 2018 guideline^[1] does not strongly prefer one over another:

• Transdermal gels (AndroGel 1% and 1.62%, Testim, Fortesta, Vogelxo). Applied daily to shoulders, upper arms, or abdomen. Produces relatively steady serum levels. Key risk: transfer to women or children from skin contact, which carries a black-box warning. This was the TRAVERSE-trial formulation.
• Intramuscular short-acting esters (testosterone cypionate, testosterone enanthate). Weekly to biweekly injections. Cheapest option in the US; the dominant cash-pay-clinic protocol. Produces supratherapeutic peaks for 1–3 days post-injection followed by a trough. Many clinics dose every 7 days subcutaneously or intramuscularly to flatten the curve.
• Intramuscular long-acting ester (testosterone undecanoate, Aveed in the US). Injection every 10–14 weeks after loading. Used in the Saad registries and T4DM. Steadier kinetics. US-Aveed access historically required REMS monitoring for pulmonary oil microembolism.
• Subcutaneous pellets (Testopel and others). Implanted in the gluteal or hip subcutaneous tissue every 3–6 months. Steady kinetics but invasive insertion; extrusion and infection are uncommon but documented.
• Nasal gel (Natesto). 3-times-daily intranasal dosing. Shortest half-life, smallest spermatogenesis-suppression footprint, useful when fertility preservation matters.
• Oral testosterone undecanoate (Jatenzo in the US; Andriol elsewhere). Twice-daily oral capsule requiring administration with food. Approved in 2019 in the US; carries blood-pressure-elevation warning (mean BP rise of ~3–5 mmHg) on the FDA label.

Convenience, cost, fertility plans, and clinician comfort drive the choice. There is no compelling efficacy difference for weight or body composition specifically among the formulations once therapeutic serum levels are achieved.

Risks, monitoring, and when TRT is not appropriate

Per the Endocrine Society 2018 guideline^[1] and the TRAVERSE safety dataset^[2]:

• Erythrocytosis (rising hematocrit) is the most common dose-limiting toxicity. Risk increases with IM-ester protocols (peak-and-trough kinetics) and in older men. Standard practice: check hematocrit at baseline, 3 months, 6 months, then every 6–12 months. Hold or reduce dose if hematocrit >54%. T4DM^[7] documented hematocrit >54% in 22% of testosterone-treated men at some point during 2 years.
• PSA monitoring at baseline, 3–12 months, then per age-appropriate prostate-cancer screening schedule. TRT does not cause prostate cancer in TRAVERSE's 33-month follow-up but can accelerate growth of pre-existing occult disease. A digital rectal exam plus baseline PSA is standard before initiation, particularly in men over 40.
• Lipids at baseline and during therapy. TRT typically lowers HDL modestly; the clinical significance is uncertain but is part of the standard monitoring panel.
• Cardiovascular signal in TRAVERSE: increased pulmonary embolism, atrial fibrillation, and acute kidney injury — counsel men with prior VTE, AFib history, or CKD specifically.
• Fertility impairment. Exogenous testosterone suppresses LH and FSH, which suppresses spermatogenesis. For men who want to conceive in the near term, TRT is relatively contraindicated — consider alternatives (clomiphene, hCG plus selective FSH replacement) that preserve gonadotropin signaling. Sperm production typically recovers months-to-years after TRT discontinuation but not always.
• Obstructive sleep apnea can worsen on TRT. Severe untreated OSA is a relative contraindication; treat OSA first.
• Acne, oily skin, mood changes are common dose-related effects.
• Gynecomastia can occur via aromatization of testosterone to estradiol, particularly in obese men.

Absolute contraindications per Bhasin 2018^[1]: active prostate cancer or breast cancer, palpable prostate nodule or PSA >4 ng/mL without urology workup, hematocrit >48–50% at baseline, untreated severe OSA, severe symptomatic lower urinary tract symptoms, uncontrolled heart failure, MI or stroke within the prior 6 months, and desire for fertility in the near term.

Cost and insurance landscape

TRT pricing in the US splits along two channels. Commercial insurance and Medicare Part D will cover TRT for diagnosed hypogonadism with two morning T values and documented symptoms; prior authorization is common, and many plans require a specialist (urology or endocrinology) consultation. Out-of-pocket cost with insurance is typically $20–$80 per month for generic IM cypionate or enanthate; gels and Jatenzo run substantially higher.

The cash-pay TRT-clinic ecosystem (Hone Health, Hims, Maximus, Henry Meds, Marek Health, dozens of regional clinics) has expanded rapidly since 2020. Typical pricing is $150–$300 per month all-in for IM testosterone cypionate plus periodic labs plus a virtual clinician visit. Quality varies widely. Red flags in any cash-pay clinic: prescribing without two morning T values, prescribing without symptom verification, no baseline PSA, no hematocrit monitoring schedule, and bundled HCG / anastrozole / clomiphene without clear indication.

Most legitimate TRT clinics follow a workup similar to endocrinology: medical history including fertility plans, baseline labs (CBC, CMP, lipids, T total + free, SHBG, LH, FSH, PSA, estradiol), discussion of risks, and a 90-day recheck before continuing. If the clinic skips any of that, find a different one.

Patient action plan

1. Confirm the diagnosis. Two morning total testosterone measurements before 10 AM on separate days, plus consistent symptoms. A single afternoon value does not justify TRT.
2. Address the cause. If you are obese with functional hypogonadism (normal LH/FSH, low T), modest weight loss often restores testosterone without exogenous hormone. Try a structured weight-loss program first when feasible. If a GLP-1 is appropriate for the obesity, that is a strong first move.
3. If TRT is indicated, see an endocrinologist or urologist with TRT experience. Get the full baseline workup (PSA, CBC for hematocrit, lipids, LH/FSH, SHBG, calculated free T, estradiol, ferritin to rule out hemochromatosis). Discuss fertility plans before any decision.
4. Choose a formulation that matches your life. IM cypionate weekly is cheapest and most common. Gel daily is steadier but requires transfer precautions. Pellets every 3–6 months minimize the dosing schedule but are invasive.
5. Commit to monitoring. Labs at baseline, 3 months, 6 months, then every 6–12 months: T (trough for IM, random for gel), hematocrit, PSA, lipids. Adjust dose to maintain T mid-normal range (~500–700 ng/dL trough) and hematocrit <52–54%.
6. Pair with resistance training and adequate protein. The body-composition benefit of TRT is amplified by resistance training and 1.6–2.0 g/kg/day of protein. Without those, the lean-mass gain is smaller.
7. Reassess every 6–12 months. If you are not getting symptom benefit at therapeutic serum levels, consider whether the original diagnosis was correct, or whether the symptoms have a non-hormonal cause (depression, sleep apnea, alcohol use, polypharmacy).

What the evidence does and doesn't say

What the TRT literature does say:

• In hypogonadal men, TRT improves libido, erectile function, mood, body composition (fat down, lean up), bone density, and glycemic control. The Endocrine Society 2018 guideline endorses TRT for symptomatic confirmed hypogonadism^[1].
• Long-term observational registries (Saad 2013^[3], 2016^[4]) document substantial sustained weight loss in obese hypogonadal men on TRT — up to 19% body weight at 8 years.
• RCTs (Ng Tang Fui 2016^[5], T4DM^[7]) show smaller scale-weight effects but consistent body-composition shifts and meaningful T2DM-prevention benefit in men with prediabetes.
• Cardiovascular safety is reassuring at the MACE endpoint (TRAVERSE^[2]), with a real signal for pulmonary embolism, atrial fibrillation, and acute kidney injury.

What the TRT literature does NOT say:

• That TRT produces weight loss in eugonadal men. There is no good evidence for TRT as a weight-loss tool in men with normal testosterone.
• That TRT is equivalent to GLP-1 receptor agonists as a weight intervention. The GLP-1s are 4–5x larger by scale-weight magnitude at matched durations.
• That the body-composition benefit is durable after discontinuation. Ng Tang Fui 2017^[6] showed reversal within a year of stopping.
• That TRT plus GLP-1 stacking is RCT-validated for weight outcomes. The combination is biologically sensible and increasingly used, but there are no published head-to-head trials.
• That cash-pay TRT clinics meet the Endocrine Society diagnostic standard. Many do not.

Bottom line

• TRT is hormone replacement for confirmed hypogonadism, not a weight-loss drug.
• In obese hypogonadal men, TRT reliably improves body composition (fat down, lean up) and may produce modest additional scale-weight loss on top of a calorie deficit.
• Long-term registries report up to 19% body-weight loss at 8 years; randomized trials report a few kilograms of extra weight loss on top of lifestyle. The truth is between them.
• The cardiovascular safety question is settled at the MACE endpoint by TRAVERSE; pulmonary embolism, atrial fibrillation, and acute kidney injury are real signals requiring informed consent.
• GLP-1 receptor agonists are the larger weight intervention in head-to-head magnitude terms.
• TRT plus GLP-1 stacking is biologically sensible for hypogonadal men with obesity; it is not yet RCT-validated.
• Diagnose correctly (two morning T plus symptoms), monitor rigorously (T, hematocrit, PSA, lipids), and pair with resistance training and adequate protein.

Related research and tools

• What to eat on a GLP-1: the protein-first guide — the meal-pattern and protein-target evidence base that pairs directly with the TRT lean-mass-preservation argument
• GLP-1 protein calculator — calculate your daily protein target (1.6–2.0 g/kg) to amplify the body-composition benefit
• Exercise pairing on a GLP-1 — the resistance-training half of the lean-mass preservation protocol
• Why am I not losing weight on a GLP-1 (the plateau guide) — covers low-testosterone as one of the under-recognized causes of poor response in men
• Semaglutide and tirzepatide — the FDA-approved weight-loss pharmacotherapies for magnitude context
• Stress, cortisol, and weight — the HPA-axis side of the male-obesity hormonal picture

Important disclaimer. This article is educational and does not constitute medical advice. Testosterone replacement therapy is a prescription medication with documented risks (erythrocytosis, prostate-monitoring requirements, fertility impairment, pulmonary embolism, atrial fibrillation, acute kidney injury). It is not a weight-loss drug. Diagnosis of hypogonadism requires two morning total testosterone values below the lab's reference range plus consistent symptoms, per the Endocrine Society 2018 Clinical Practice Guideline. Patients considering TRT should consult an endocrinologist or urologist, complete a full baseline workup (CBC, CMP, lipids, T total and free, SHBG, LH, FSH, PSA, estradiol), and commit to lifelong monitoring. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if a new TRT cardiovascular, prostate, or weight-outcome trial is published.